Updated: Oct 20
Medically reviewed by ChinaCureLink Team
Table of Content
Introduction
Patients researching bronchiectasis may encounter airway basal stem cell therapy as an emerging treatment option. In China, this therapy is currently available through the Boao Lecheng medical-access pathway in Hainan. This guide explains what the treatment is, who may be considered, its estimated cost, and what international patients should know before pursuing it.
Key Takeaways |
|
What Is Airway Basal Stem Cell Therapy?
Airway basal stem cells are adult stem cells found in the base of the airway epithelium. The treatment uses these cells for local transplantation into damaged airways, with the intended role of supporting airway epithelial repair and regeneration.
For patients with bronchiectasis, the treatment is considered in the context of ongoing disease management. Standard care focuses on symptom control and slowing disease progression. The treatment pathway described here is intended for patients for whom standard care is considered insufficient.
Clinical evidence for airway basal stem cell approaches remains under evaluation. Availability through a medical-access pathway should not be interpreted as proof of effectiveness or as a guarantee of an individual outcome.
Is Airway Basal Stem Cell Therapy Available in China?
Yes. Airway basal stem cell therapy for bronchiectasis is included in the second batch of approved Boao Lecheng projects in Hainan.
Boao Lecheng provides a supervised pathway through which certain approved medical technologies can be accessed at designated institutions. This is different from nationwide approval for routine use throughout China.
International patients therefore need to confirm current project availability, medical eligibility, and the hospital's acceptance process before making travel arrangements.
Where Is the Treatment Offered?
The treatment is offered at Shanghai Jiao Tong University Affiliated Ruijin Hospital Hainan Hospital (Hainan Boao Research Hospital) in Hainan.
Technical support is provided by Suzhou Jimerris Medical Technology Co., Ltd.
The treatment uses airway basal stem cells, with local transplantation into damaged airways as the stated administration method.
Who May Be Eligible?
There are no fixed published eligibility criteria for this treatment. Professional medical evaluation is used to determine whether a patient with bronchiectasis may be considered.
The treatment is intended for bronchiectasis patients for whom standard care focused on symptom control and slowing progression is insufficient.
Patients should provide relevant medical records, diagnostic information, previous treatment history, and details of their current condition for review. Final eligibility is determined by the treating medical team after reviewing the patient's medical records and conducting the required medical assessment.
How Much Does It Cost?
The estimated cost is ¥150,000 (approximately US$22,300) per injection. The USD figure uses a reference exchange rate of about ¥6.72 per US$1 and can change with currency movements.
The stated price does not necessarily include consultation, hospitalization, translation or coordination, or travel expenses. Patients should confirm the full scope of the treatment price and any additional costs directly with the hospital before arranging travel.
Why International Patients May Consider This Option
For some international patients with bronchiectasis, access to an emerging airway-repair approach may provide another option to discuss with specialists when standard disease management has not provided sufficient control.
The Boao Lecheng pathway provides a specific route for exploring this treatment in China. Patients considering it should compare the treatment with established management options, understand the available clinical evidence, and discuss potential benefits, risks, eligibility, and alternatives with qualified physicians.
How ChinaCureLink Can Help Patients Access This Treatment
We help international patients explore available treatment options and facilitate communication with appropriate medical specialists. Patients should discuss potential benefits, risks, eligibility, and alternatives directly with qualified physicians. ChinaCureLink does not represent or endorse the treatment technology, manufacturer, or hospital.
Case review: We collect relevant medical history and COPD-management records to help determine whether a case is appropriate for physician review.
Hospital coordination: We help connect patients with the treating team at 2-3 Eligible Hospitals in for an initial assessment.
Online consultation before travel: Patients can discuss potential eligibility, the procedure, and expected next steps with the medical team remotely before committing to international travel.
Coordination support: Depending on the case, this can include translation assistance, appointment scheduling, and logistics coordination.
Considering This Treatment in China?
Before planning travel, speak with a qualified specialist to determine whether the treatment is appropriate for your condition and whether you meet the medical eligibility requirements.
ChinaCureLink can help international patients arrange a specialist review and explore airway basal stem cell therapy for bronchiectasis in China. Request a Medical Review / Speak With a Specialist
Get a Second Opinion Before Fly to China
For suitable cases, ChinaCureLink can then coordinate an online consultation with the specialist to discuss the technical treatment details directly. The purpose is to help the patient understand which treatment option and which specialist center may be most appropriate before making an international treatment decision.
What Patients Say About ChinaCureLink & Medebound HEALTH
China CureLink operates under Medebound HEALTH — an internationally recognized healthcare navigation company incorporated in New York, with operations across North America and Asia-Pacific.
Rated 4.6 ⭐⭐⭐⭐⭐ at Trustpilot
Medebound HEALTH's online testimonials. Learn More
★★★★☆ Sarah Zhang · Canada· Jul 2024 · Verified “The interpreter during the video call was fantastic — super professional and answered all our questions clearly and quickly. The professor was also very patient and gave us detailed and honest guidance on our treatment options.” |
★★★★★ Andrew Goh · Singapore · Aug 2024 · Verified “My first contact with Medebound was over a year ago. Jason has always been responsive, even when I wasn't ready to proceed. When I finally did, the consultation was seamlessly arranged and the specialist was outstanding.” |
★★★★★ Daniel Wong · Singapore · Aug 2024 · Verified “I have dry eye and nothing seemed to be working, even with different medications. I heard about a medication from the U.S. that’s supposed to be really effective, but I didn’t want to try it without talking to a doctor first. MEDEBOUND connected me with a top ophthalmologist in the U.S. and it was so reassuring to get their expert advice.” |
★★★★☆ Pongsakorn · Thailand · Feb 2025 · Verified “Kiki at Medebound is amazing — so professional and helpful! They got my video consultation with an MD Anderson expert set up super fast, within just 5 working days. I am so grateful for their support.” |
Frequently Asked Questions
Is airway basal stem cell therapy for bronchiectasis available in China?
Yes. It is included in the second batch of approved Boao Lecheng projects and is available through the designated pathway in Hainan, subject to medical evaluation and current hospital access.
How much does airway basal stem cell therapy cost in China?
The estimated cost is ¥150,000, approximately US$22,300, per injection. Confirm final pricing and what the price covers directly with the hospital.
Who may qualify for airway basal stem cell therapy for bronchiectasis?
There are no fixed published criteria. Professional evaluation determines whether the treatment may be appropriate for a bronchiectasis patient whose standard care is insufficient.
Can international patients receive this treatment in China?
International patients can explore the treatment through the Hainan Boao Lecheng pathway, subject to medical assessment, eligibility, and acceptance by the treating hospital.
About ChinaCureLink
ChinaCureLink helps patients across the world access the best cancer treatment at China's top hospitals, without the delays, language barriers, and administrative confusion that typically come with seeking care abroad.
We connect patients directly with China's top cancer hospitals, ensuring that from the first case submission through to treatment and follow-up, every step is guided, translated, and coordinated by a team experienced in cross-border patient care.
ChinaCureLink is proudly affiliated with Medebound HEALTH — founded by US physicians, with over 10 years of experience and more than 3,000 patients served worldwide, Medebound HEALTH is recognized by Forbes and it is one of the most trusted patient cross-border concierge service company across North America and the Asia Pacific.
Disclaimer
This article is for informational purposes only and is not medical or financial advice. Treatment eligibility, protocols, and costs vary by individual case — confirm specifics with a coordinator and treating physician before making any decisions.
